Fluconazole
- Generic Name
- Fluconazole
- Brand Names
- Diflucan
- Drug Type
- Small Molecule
- Chemical Formula
- C13H12F2N6O
- CAS Number
- 86386-73-4
- Unique Ingredient Identifier
- 8VZV102JFY
- Background
Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...
- Indication
Fluconazole can be administered in the treatment of the following fungal infections:
1) Vaginal yeast infections caused by Candida
2) Systemic Candida infections
3) Both esophageal and oropharyngeal candidiasis
4) Cryptococcal meningitis
5) UTI (urinary tract infection) by Candida
6) Peritonitis (inflammation of the peritoneum) caused by Candida
...
- Associated Conditions
- Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
- Associated Therapies
- -
Vietnam Cryptococcal Retention in Care Study Version 1.0
- First Posted Date
- 2015-01-08
- Last Posted Date
- 2017-09-13
- Target Recruit Count
- 2612
- Registration Number
- NCT02334670
- Locations
- 🇻🇳
National Hospital for Tropical Diseases, Hanoi, Vietnam
Drug-Drug Interaction Study in Healthy Adult Volunteers
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02275975
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02244606
- Locations
- 🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸South Texas Veterans Healthcare System, San Antonio, Texas, United States
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 138
- Registration Number
- NCT02222922
- Locations
- 🇺🇸
Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸Stanford Hospital and Clinics, Stanford, California, United States
Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02181946
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
- Conditions
- Interventions
- First Posted Date
- 2014-07-03
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 240
- Registration Number
- NCT02180828
- Locations
- 🇨🇳
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
- Conditions
- Interventions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT02180100
- Locations
- 🇨🇳
Peking University Shenzhen Hosptal, Shenzhen, Guangdong, China
Fluconazole Versus Micafungin in Neonates With Candidiasis
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2014-05-23
- Target Recruit Count
- 100
- Registration Number
- NCT02145832
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 51
- Registration Number
- NCT02122770
- Locations
- 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
🇺🇸Siteman Cancer Center - South County, Saint Louis, Missouri, United States
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02093390
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.